Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

Table 4

Pathologic partial and complete response rates GC versus MVAC.

	Complete response rate (pT0)
Neoadjuvant chemotherapy	Yes	No	𝑃 value	OR (95% CI)*
GC	12 (29%)	29 (71%)	0.52	1.00 (referent)
MVAC	7 (22%)	24 (78%)		0.39 (0.10–1.58)
	Complete + partial response rate (<pT1)
Neoadjuvant chemotherapy	Yes	No		OR (95% CI)∗
GC	20 (49%)	21 (51%)	0.26	1.00 (referent)
MVAC	11 (35%)	20 (62%)		0.45 (0.12–1.71)

∗Adjusted for age, gender, race, clinical stage, completion of diagnostic resection, cardiac disease, and creatinine.